Last reviewed · How we verify
AR101 powder provided in capsules — Competitive Intelligence Brief
phase 2
oral immunotherapy
Allergy
Biologic
Live · refreshed every 30 min
Target snapshot
AR101 powder provided in capsules (AR101 powder provided in capsules) — Aimmune Therapeutics, Inc.. AR101 is an oral immunotherapy for peanut allergy.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AR101 powder provided in capsules TARGET | AR101 powder provided in capsules | Aimmune Therapeutics, Inc. | phase 2 | oral immunotherapy | ||
| Multi-Allergen Oral Immunotherapy | Multi-Allergen Oral Immunotherapy | National Institute of Allergy and Infectious Diseases (NIAID) | phase 3 | Oral immunotherapy (OIT) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (oral immunotherapy class)
- Aimmune Therapeutics, Inc. · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AR101 powder provided in capsules CI watch — RSS
- AR101 powder provided in capsules CI watch — Atom
- AR101 powder provided in capsules CI watch — JSON
- AR101 powder provided in capsules alone — RSS
- Whole oral immunotherapy class — RSS
Cite this brief
Drug Landscape (2026). AR101 powder provided in capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/ar101-powder-provided-in-capsules. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab